FDA grants special designations to Cary startup’s drug that targets developmental disorder in children
A drug being developed by Cary-based Rescindo Therapeutics for treating a rare developmental disorder in children has received two special designations from the U.S. Food and Drug Administration that will help the company advance the potential therapy.
Read More
